The future of COVID-19 management: A spotlight on respirology
10 Jan 2024;
At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.
Contents : Meningococcal group A, C, W & Y conjugate vaccine
Indications/Uses : Active immunisation of individuals ≥12 mth against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W & Y.
Indications/Uses : Prevention of flu caused by 2 influenza A virus subtypes & 2 influenza B virus types contained in the vaccine for active immunisation of adults, pregnant women & childn ≥6 mth.
Indications/Uses : Adults, infants ≥3 mth, childn & adolescents w/ complicated intra-abdominal infection (cIAI) (in combination w/ metronidazole); complicated UTI (cUTI) including pyelonephritis; hospital-acquired pneumonia (HAP) including ventilator associated pneumonia (VAP). Adults w/ bacteraemia that occurs in association w/ or is suspected to be associated w/ cIAI, cUTI or HAP/VAP.
Sign Out
